ASIT biotech


€5.1m market cap

€0.23 last close

ASIT biotech is a clinical-stage company focused on developing therapies for allergies. It uses its proprietary ASIT+ technology platform to develop products containing highly purified allergen fragments in an adjuvant-free formulation, selected to be safe while maintaining the capacity to stimulate immune tolerance.

Investment summary

Reported gp-ASIT+ Phase III allergy data showed a statistically proven but inadequate clinical response. Management is exploring strategic options in H120. The board is cutting costs and on 11 February obtained the benefit of a judicial reorganisation by collective agreement. The annual report was published on 7 May. An EGM is called for 26 May with the OGM on 15 June. Cash in December was €3.7m. A plan to repay creditors will be provided. Our forecasts and valuation are withdrawn.

Y/E Dec
Revenue (€m)
PBT (€m)
EPS (c)
P/E (x)
P/CF (x)
2017A 0.0 (12.0) (12.0) (93.6) N/A N/A
2018A 0.0 (12.8) (14.3) (85.7) N/A N/A
2019E N/A N/A N/A N/A N/A N/A
2020E N/A N/A N/A N/A N/A N/A
Industry outlook

gp-ASIT+ is a short-course pre-seasonal treatment that aims to reduce the cellular response to pollen and induce blocking antibodies without generating an immediate allergic response.

Last updated on 28/05/2020
Share price graph
Balance sheet
Forecast net debt (€m) N/A
Forecast gearing ratio (%) N/A
Price performance
Actual (16.6) 8.7 (82.5)
Relative* (20.7) 15.5 (81.4)
52-week high/low €2.6/€0.2
*% relative to local index
Key management
Michel Baijot CEO
Frank Hazevoets CFO
Yves Desiront CFO